Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. (Q54323723)

27 May 2018

title

Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. (English)

1 reference

27 May 2018

1 reference

Robert Shumaker

1

1 reference

27 May 2018

Jagadeesh Aluri

2

1 reference

27 May 2018

Jean Fan

3

1 reference

27 May 2018

Gresel Martinez

4

1 reference

27 May 2018

Helen Pentikis

5

1 reference

27 May 2018

Min Ren

6

1 reference

27 May 2018

publication date

25 September 2014

1 reference

27 May 2018

The Journal of Clinical Pharmacology

published in

1 reference

27 May 2018

volume

55

1 reference

27 May 2018

issue

3

1 reference

27 May 2018

page(s)

317-327

1 reference

27 May 2018

Are tumours angiogenesis-dependent?

cites work

1 reference

Angiogenesis: update 2005.

21 January 2018

1 reference

The biology of VEGF and its receptors

21 January 2018

1 reference

Modes of resistance to anti-angiogenic therapy

21 January 2018

1 reference

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

21 January 2018

1 reference

Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase

21 January 2018

1 reference

E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition

21 January 2018

1 reference

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

21 January 2018

1 reference

Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.

21 January 2018

1 reference

Evaluation of the effects of formulation and food on the pharmacokinetics of lenvatinib (E7080) in healthy volunteers.

21 January 2018

1 reference

A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

21 January 2018

1 reference

Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability

21 January 2018

1 reference

Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics

21 January 2018

1 reference

Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.

21 January 2018

1 reference

Effects of hepatic impairment on the pharmacokinetics of nilotinib: an open-label, single-dose, parallel-group study

21 January 2018

1 reference

Pharmacokinetics of sunitinib malate in subjects with hepatic impairment

21 January 2018

1 reference

Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432.

21 January 2018

1 reference

Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.

21 January 2018

1 reference

Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group

21 January 2018

1 reference

Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301

21 January 2018

1 reference

The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JCPH.398

1 reference

27 May 2018

1 reference

27 May 2018